John NM, Wright SJ, Gavan SP, Vass CM. The role of information provision in economic evaluations of non-invasive prenatal testing: a systematic review. Eur J Health Econ. 2019 Nov;20(8):1123-31. doi: 10.1007/s10198-019-01082-x
Pead E, Megaw R, Cameron J, Fleming A, Dhillon B, Trucco E, MacGillivray T. Automated detection of age-related macular degeneration in color fundus photography: a systematic review. Surv Ophthalmol. 2019 Jul 1;64(4):498-511. doi: 10.1016/j.survophthal.2019.02.003
McInerney KA, Hahn KA, Hatch EE, Mikkelsen EM, Steiner AZ, Rothman KJ, Sorensen HT, Snerum TM, Wise LA. Lubricant use during intercourse and time-to-pregnancy: a prospective cohort study. BJOG. 2018 Nov;125(12):1541-8. doi: 10.1111/1471-0528.15218
Wilson MR, Bergman A, Chevrou-Severac H, Selby R, Smyth M, Kerrigan MC. Cost-effectiveness of vedolizumab compared with infliximab, adalimumab, and golimumab in patients with ulcerative colitis in the United Kingdom. Eur J Health Econ. 2017 Mar;19(2):229-40. doi: 10.1007/s10198-017-0879-5.
Rodriguez A, Garcia-Esteban R, Basterretxea M, Lertxundi A, Rodriguez‐Bernal C, Iniguez C, Rodriguez‐Dehli C, Tardon A, Espada M, Sunyer J, Morales E. Associations of maternal circulating 25-hydroxyvitamin D3 concentration with pregnancy and birth outcomes. BJOG. 2015 Nov;122(12):1695-704. doi: 10.1111/1471-0528.13074
Beard SM, von Scheele BG, Nuki G, Pearson IV. Cost-effectiveness of febuxostat in chronic gout. Eur J Health Econ. 2013 May;Advance online publication.
Pitchforth E, Watson V, Tucker J, Ryan M, van Teijlingen E, Farmer J, Ireland J, Thomson E, Kiger A, Bryers H. Models of intrapartum care and women's trade-offs in remote and rural Scotland: a mixed-methods study. BJOG. 2008 Apr;115(5):560-9. doi: 10.1111/j.1471-0528.2007.01516.x
Heintz E, Brodtkorb T, Nelson N, Levin LA. The long-term cost-effectiveness of fetal monitoring during labour: a comparison of cardiotocography complemented with ST analysis versus cardiotocography alone. BJOG. 2008;115(13):1676-87.
Greiner W, Lehmann K, Earnshaw S, Bug C, Sabatowski R. Economic evaluation of Durogesic in moderate to severe, nonmalignant, chronic pain in Germany. Eur J Health Econ. 2006 Dec 1;7(4):290-6.
Strickland A, Brogan AJ, Krauss J, Martindale R, Cresci G. Is the use of specialized nutritional formulations a cost-effective strategy? A national database evaluation. J Parenter Enter Nutr. 2005 Jan 1;29(1 Suppl):S81-91.
Lehmann K, Radbruch L, Gockel HH, Neighbors D, Nuyts G. Costs of opioid therapy for chronic nonmalignant pain in Germany: an economic model comparing transdermal fentanyl (Duragesic) with controlled release morphine. Eur J Health Econ. 2002;3:111-9. doi: 10.1007/s10198-002-0097-6.
Clarkson TB, Anthony MS, Klein KP. Hormone replacement therapy and coronary artery atherosclerosis: the monkey model. BJOG. 1996 May;103(Suppl 13):53-7.